HDM2024 / Huadong Medicine - LARVOL DELTA

Huadong Medicine…announced that HDM2024, a Category 1 innovative bispecific antibody-drug conjugate (Bs-ADC), has received FDA clearance to initiate a Phase I clinical trial for the treatment of advanced solid tumors (flcube.com) - "The first-in-class candidate simultaneously targets EGFR (HER1) and HER3, delivering a DNA topoisomerase I inhibitor payload via a cleavable linker to block proliferative signaling while exerting direct cytotoxic antitumor effects."

New P1 trial • Solid Tumor